Home / Resources (page 30)

Resources

RESOURCES

Off-Ramp Planning for GLP-1s: When and How to Taper Without Losing Progress

Physician reviewing a gradual medication dose reduction chart with a patient during a consultation about GLP-1 tapering and metabolic health goals.

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

Read More »

GLP-1s and Food Noise: Helping Patients Understand Hunger, Cravings, and Control

Woman calmly eating a healthy meal while unhealthy foods fade around her, illustrating reduced GLP-1 food noise and improved appetite control.

Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …

Read More »

GLP-1s in Young Adults: Rethinking Metabolic Risk and Early Intervention

Young adults consulting with a physician about GLP-1 therapy for obesity and early metabolic risk management

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

Read More »

Social Determinants First: Using CKM and SDOH to Sequence Diabetes Therapies in 2026

Clinician reviewing cardiovascular, kidney, and metabolic risk with social determinants to guide diabetes therapy decisions

A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …

Read More »

Diabetes Care in the GLP-1 Era: Re-Designing Visits When One Drug Does So Much

Doctor reviewing diabetes metrics with patient during a GLP-1 era clinic visit using digital health tools

GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …

Read More »

GLP-1s and Serious Mental Illness: Tackling Antipsychotic-Associated Weight Gain

GLP-1 injection pen and metabolic monitoring tools illustrating treatment for antipsychotic-related weight gain

For many patients, antipsychotic medications are life-changing, even life-saving. Yet the same treatments that stabilize mood and thought can quietly drive weight gain, insulin resistance, and rising cardiometabolic risk. Over time, this unintended consequence places patients with serious mental illness at a much higher risk for obesity, type 2 diabetes, …

Read More »

GLP-1s and Lean Mass: Preserving Muscle and Strength During Rapid Weight Loss

GLP-1 medications support weight loss, but lean mass loss is a concern. Learn how to protect muscle, strength, and function during GLP-1 therapy.

The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …

Read More »

GLP-1s and Dermatologic Disease: From Psoriasis to Hidradenitis—Signal or Noise?

Dermatologist examining inflammatory skin lesions in a patient using GLP-1 therapy

A patient returns for follow-up after starting a GLP-1 receptor agonist and mentions something unexpected. Their blood glucose is improved, weight is down, and their psoriasis seems quieter. Another patient reports fewer hidradenitis flares. These anecdotes are becoming more common, raising a practical question for clinicians. Are GLP-1 therapies influencing …

Read More »